Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond

(2015) Tobias Ruck et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

(2014) O. Tuohy et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis

(2013) L. Azzopardi et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab Mediated Cytolysis

(2012) Sambasiva P. Rao et al.   PLoS One

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis

(2011) A. Cuker et al.   BLOOD

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

(2011) Grant A Hill-Cawthorne et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

(2011) M. Cossburn et al.   NEUROLOGY

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE